Applied Biosystems announced this week the release of a new series of TaqMan Gene Signature Panels for accelerating drug discovery research.
“Researchers who use these gene signature panels, which are offered in low density array formats, will be able to more thoroughly study difficult-to-detect genes that are important to the drug research needs of the pharmaceutical industry,” the company said in a release.
Some of the proteins addressed by the new gene signature panels are G-protein coupled receptors, cell-surface receptors that act as signaling proteins for various critical cell functions. According to several published research articles, at least 40 percent of recently developed drugs modulate the action of GPCRs, Applied Biosystems said.
Currently, there are marketed drugs that target GPCRs for heart failure, high blood pressure, breast cancer, and schizophrenia. Pharmaceutical companies can also use the GPCR panels to prioritize which tissues to study further.
Applied Biosystems also announced the availability of a new panel for the apoptosis pathway, a group of proteins related to programmed cell death that can be used to evaluate the effectiveness of oncolgoics.
Illumina announced this week that it has introduced a flexible, high-throughput DNA methylation profiling technology with the ability to survey as many as 1,536 methylation sites across 96 samples simultaneously.
The technology combines Illumina's BeadArray platform with the GoldenGate assay approach, the first standard panel that covers 1,505 methylation sites over 800 cancer genes. The combined platform enables researchers to perform genome-wide methylation profiling across multiple areas such as cancer and human embryonic stem cell research.
Illumina's GoldenGate Assay for Methylation was beta tested at the Norris Comprehensive Cancer Center of the University of Southern California and the National Cancer Institute.
“Both sites reported assay robustness, ease of use, and high-throughput and high-multiplex methylation interrogation with a streamlined workflow,” Illumina said.
The company is hosting a webinar to discuss its new DNA methylation profiling and end-user experience in cancer research on Feb. 12.